Tvardi Therapeutics Income Statement

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022
Period Ending	Sep '25 Sep 30, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022
Selling, General & Admin	8.84	4.46	2.8	2.73
Research & Development	21.12	23.65	15.87	18.47
Operating Expenses	29.96	28.11	18.67	21.19
Operating Income	-29.96	-28.11	-18.67	-21.19
Interest Expense	-	-	-	-0
Interest & Investment Income	1.2	0.75	1.32	0.65
Other Non Operating Income (Expenses)	5.12	-2.04	-	-
Pretax Income	-23.65	-29.4	-17.35	-20.54
Net Income	-23.65	-29.4	-17.35	-20.54
Net Income to Common	-23.65	-29.4	-17.35	-20.54
Shares Outstanding (Basic)	10	6	6	6
Shares Outstanding (Diluted)	10	6	6	6
Shares Change (YoY)	170.52%	0.31%	0.09%	-
EPS (Basic)	-2.48	-4.59	-2.72	-3.22
EPS (Diluted)	-3.23	-4.59	-2.72	-3.22
Free Cash Flow	-22.65	-18.31	-21.04	-17.92
Free Cash Flow Per Share	-2.38	-2.86	-3.30	-2.81
EBITDA	-29.87	-28.01	-18.57	-21.11
D&A For EBITDA	0.1	0.1	0.1	0.09
EBIT	-29.96	-28.11	-18.67	-21.19

Source: S&P Global Market Intelligence. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q